Profile data is unavailable for this security.
About the company
Fagron NV, formerly Arseus NV, is a Belgium-based company that is active in the healthcare sector. The Company specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. It operates through the following segments: Essentials, enable pharmacists to compound safe products and optimize their compounding process with equipment and packaging. The portfolio includes pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, focuses on developing semi-finished products and pharmaceutical-grade vehicles and reduce the workload for pharmacists; Compounding Services, utilizes raw materials from the Essentials segment and vehicles from the Brands segment for compounding activities, offering both sterile and non-sterile compounded products tailored to patients' specific needs.
- Revenue in EUR (TTM)871.96m
- Net income in EUR80.55m
- Incorporated2007
- Employees3.94k
- LocationFagron NVVenecoweg 20ANAZARETH 9810BelgiumBEL
- Phone+32 80012880
- Fax+32 92162491
- Websitehttps://fagron.com/
More ▼
Mergers & acquisitions
| Acquired company | FAGR:BRU since announced | Transaction value |
|---|---|---|
| Guinama SLU | 16.07% | 22.76m |
| CareFirst Specialty Pharmacy LLC | 34.43% | -- |
| Industrial E Comercial Injecao Plastica Injeplast Ltda | 34.43% | -- |
Data delayed at least 15 minutes, as of Jul 18 2025 16:35 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 219.84m | 58.80m | 1.55bn | 2.03k | 26.31 | 4.46 | -- | 7.04 | 1.55 | 1.55 | 5.87 | 9.16 | 0.4006 | 1.16 | 4.15 | 904,626.50 | 10.55 | 7.19 | 15.64 | 9.67 | 67.91 | 59.30 | 26.33 | 20.28 | 0.7316 | 23.05 | 0.4204 | 35.89 | 57.21 | 34.33 | 148.19 | 52.76 | 31.58 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 432.90m | 89.75m | 1.55bn | 2.44k | 17.21 | 3.91 | -- | 3.59 | 1.33 | 1.33 | 6.41 | 5.84 | 0.6952 | 2.15 | 10.07 | 1,483,590.00 | 14.41 | 11.90 | 23.44 | 18.89 | 74.86 | 74.36 | 20.73 | 16.46 | 0.8157 | -- | 0.0259 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Ocular Therapeutix Inc | 51.30m | -165.76m | 1.56bn | 274.00 | -- | 6.82 | -- | 30.39 | -1.15 | -1.15 | 0.3559 | 1.67 | 0.1263 | 1.90 | 2.30 | 217,686.10 | -40.79 | -44.65 | -43.67 | -51.24 | 90.67 | 90.65 | -323.09 | -216.33 | 10.14 | -- | 0.2065 | -- | 9.03 | 72.05 | -139.68 | -- | -10.46 | -- |
| Immunocore Holdings PLC - ADR | 286.93m | -18.60m | 1.56bn | 493.00 | -- | 9.60 | -- | 5.45 | -0.4451 | -0.4451 | 6.51 | 3.77 | 0.33 | 0.6045 | 5.52 | 676,634.90 | -2.14 | -17.90 | -2.52 | -23.26 | 99.01 | -- | -6.48 | -53.74 | 6.31 | -- | 0.5085 | -- | 24.37 | 56.77 | 7.60 | -- | -1.06 | -- |
| Vericel Corp | 205.18m | 2.56m | 1.57bn | 357.00 | 599.74 | 6.17 | 182.95 | 7.65 | -0.0141 | -0.0141 | 4.58 | 5.88 | 0.6107 | 4.27 | 4.64 | 668,182.10 | 0.7624 | -1.03 | 0.8444 | -1.18 | 72.54 | 69.10 | 1.25 | -1.61 | 4.58 | -- | 0.0023 | -- | 20.10 | 15.02 | 425.64 | -- | 89.53 | -- |
| Arcutis Biotherapeutics Inc | 183.05m | -111.57m | 1.59bn | 342.00 | -- | 12.93 | -- | 8.67 | -1.04 | -1.04 | 1.71 | 1.20 | 0.5174 | 1.65 | 3.47 | 622,277.80 | -31.54 | -61.20 | -37.92 | -68.48 | 88.39 | -- | -60.95 | -406.29 | 3.37 | -5.35 | 0.43 | -- | 229.74 | -- | 46.58 | -- | 77.12 | -- |
| Fagron NV | 871.96m | 80.55m | 1.59bn | 3.94k | 19.65 | 3.15 | 13.56 | 1.82 | 1.10 | 1.10 | 11.95 | 6.88 | 0.8342 | 3.80 | 12.11 | 221,590.80 | 7.75 | 7.68 | 9.46 | 9.64 | 45.38 | 43.75 | 9.29 | 9.96 | 1.16 | 5.05 | 0.4329 | 19.12 | 14.28 | 10.28 | 14.18 | 7.85 | 12.97 | 34.34 |
| Caplin Point Laboratories Ltd | 193.44m | 53.55m | 1.60bn | 859.00 | 30.00 | 5.62 | 26.41 | 8.28 | 70.32 | 70.32 | 254.06 | 375.35 | 0.656 | 2.21 | 3.30 | -- | 18.32 | 19.09 | 20.80 | 21.89 | 60.21 | 55.55 | 27.93 | 26.11 | 5.87 | 937.03 | 0.0017 | -- | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | -- |
| Luye Pharma Group Ltd | 726.44m | 56.55m | 1.61bn | 5.15k | 28.44 | 0.9479 | 9.35 | 2.21 | 0.1372 | 0.1372 | 1.76 | 4.11 | 0.22 | 2.32 | 2.78 | 1,286,888.00 | 2.34 | 1.98 | 3.84 | 3.16 | 66.72 | 68.37 | 10.64 | 8.04 | 1.15 | 3.01 | 0.4001 | 0.00 | -1.33 | -0.9503 | -11.40 | -19.50 | -10.95 | -- |
| Tsumura & Co | 1.05bn | 187.41m | 1.61bn | 4.27k | 8.49 | 0.9143 | 6.09 | 1.54 | 427.12 | 427.12 | 2,385.35 | 3,968.06 | 0.4058 | 0.72 | 2.73 | 42,390,680.00 | 7.74 | 5.53 | 9.75 | 6.85 | 50.02 | 49.39 | 19.06 | 14.50 | 2.62 | -- | 0.1766 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Supernus Pharmaceuticals Inc | 574.57m | 53.25m | 1.62bn | 674.00 | 30.41 | 1.82 | 13.25 | 2.82 | 1.10 | 1.10 | 11.93 | 18.41 | 0.5039 | 1.10 | 4.55 | 991,093.50 | 4.67 | 4.25 | 6.03 | 5.58 | 89.75 | 87.90 | 9.27 | 10.41 | 2.26 | -- | 0.00 | -- | 8.94 | 11.00 | 5,512.84 | -8.16 | -23.33 | -- |
Data as of Jul 18 2025. Currency figures normalised to Fagron NV's reporting currency: Euro EUR
48.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Goldman Sachs Asset Management BVas of 23 Apr 2025 | 13.21m | 18.04% |
| Active Ownership Corp SARLas of 23 Apr 2025 | 8.10m | 11.07% |
| Mawer Investment Management Ltd.as of 23 Apr 2025 | 3.68m | 5.02% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 2.32m | 3.17% |
| Fidelity Management & Research Co. LLCas of 31 May 2025 | 2.25m | 3.08% |
| abrdn Investment Management Ltd.as of 31 Mar 2025 | 1.57m | 2.14% |
| Amundi Asset Management SASU (Investment Management)as of 02 Jul 2025 | 1.22m | 1.67% |
| BNP Paribas Asset Management Belgium SAas of 30 Aug 2024 | 1.18m | 1.62% |
| KBC Asset Management NVas of 31 Dec 2024 | 1.18m | 1.61% |
| Tweedy, Browne Co. LLCas of 30 Apr 2025 | 1.12m | 1.53% |
More ▼
Data from 31 Mar 2025 - 09 Jul 2025Source: FactSet Research Systems Inc.
